NewAmsterdam Pharma Company N.V. (NAMS) Research

NewAmsterdam Pharma Company N.V. functions as a clinical-phase biopharmaceutical enterprise, dedicated to enhancing treatment outcomes for patients dealing with metabolic disorders. The company's principal experimental medication, obicetrapib, represents a pioneering and targeted inhibitor that acts on the Cholesteryl Ester Transfer Protein (CETP). This compound has demonstrated in clinical studies its capacity to lower low-density lipoprotein cholesterol (LDL-C) and, concurrently, significantly elevate high-density lipoprotein cholesterol (HDL-C). Established in 2019, the company is headquartered in Naarden, the Netherlands.

Market snapshot

Symbol
NAMS
Price
$29.83
Day change
-1.06%
Market cap
$3.5B
P/E ratio
-16.98x
52-week range
17.63-42.205
Sector
Healthcare
Industry
Biotechnology
Next earnings
in 2 months
Analyst price target
$49.00

Peer companies

  • Arcellx, Inc. (ACLX)
  • Akero Therapeutics, Inc. (AKRO)
  • CG Oncology, Inc. Common stock (CGON)
  • Crinetics Pharmaceuticals, Inc. (CRNX)
  • Immunovant, Inc. (IMVT)
  • Kymera Therapeutics, Inc. (KYMR)
  • Ligand Pharmaceuticals Incorporated (LGND)
  • Praxis Precision Medicines, Inc. (PRAX)

Recent insider activity

  • Kooij Louise Frederika — M-Exempt (5000 shares) on 2026-05-26
  • Kooij Louise Frederika — M-Exempt (60000 shares) on 2026-05-26
  • Kooij Louise Frederika — M-Exempt (60000 shares) on 2026-05-26
  • Kooij Louise Frederika — M-Exempt (5000 shares) on 2026-05-26
  • Kooij Louise Frederika — S-Sale (65000 shares) on 2026-05-26

Open NewAmsterdam Pharma Company N.V. (NAMS) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.